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and mean possession ratios (MPR) and were calculated at a 3–6
month timeframe for all study participants and compared to
usual care. RESULTS: During the 7-month enrollment period a
total of 6833 members were randomized to the intervention
group for call one, 3274 for call two, 772 for call three, and
4172 to usual care. Members reached for each intervention
group were 3723 for call one, 1427 for call two, and 339 for
call three. Targeted members demonstrated statistically signiﬁ-
cant higher rates of persistency compared to the control group
(49.2% vs 44.70%). MPRs were also statistically signiﬁcantly
higher for members receiving telephonic intervention at 3–6
months (0.759 vs 0.738). These differences were seen regardless
of age and gender. CONCLUSION: Compliance with statin
therapy remains poor, however IVR technology can improve
adherence to statins in new start patients. Additional studies are
needed to evaluate the use of IVR technology in combination
with other more traditional compliance methods.
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OBJECTIVES: To assess whether new users of antihypertensive
therapy could beneﬁt from using a single-pill, ﬁxed-dose combi-
nation drug compared with separate pills to improve their adher-
ence to therapy. METHODS: Data from the Integrated Primary
Care Information database in The Netherlands (NL) and 30
Italian (IT) general practitioners with automated medical records
were used. Patients aged ≥30 y with mild-to-moderate hyperten-
sion and ≥3 cardiovascular risk factors or prior cardiovascular
events who were experienced or new users of antihypertensives
in June 2003–June 2004 (NL) or June 2004-June 2005 (IT) were
selected. Patients were followed until October 2005 (NL) or Feb-
ruary 2006 (IT) when they completed a questionnaire concern-
ing adherence to their therapy. Treatment adherence (percentage
of days covered [PDC]) was also calculated from the prescrip-
tion records. RESULTS: A total of 729/1473 (49.5%) (NL) and
1320/1602 (82.4%) (IT) completed the questionnaire. Of these,
101 (NL) and 47 (IT) patients were new users of antihyperten-
sives. Reasons for not taking medications were side effects, inef-
fectiveness and forgetfulness, which scored highest in the NL. In
Italy, forgetfulness and side effects were ranked highest. The
median PDC for antihypertensive drugs was 57% (NL) and 69%
(IT), less than 40% (NL) and 42% (IT) had PDC > 80%. Partial
(PDC 20–80%) and poor (PDC < 20%) adherence occurred fre-
quently in newly treated hypertensive patients. Approximately
35% (NL) and 70% (IT) of the respondents stated that they
would be less or much less likely to miss a dose with a single pill
combination therapy. The likelihood to miss a dose with single-
pill treatment was not associated with the prescription-derived
PDC levels, but highly associated with self-reported level of
adherence. CONCLUSION: Patients newly treated with antihy-
pertensive drugs with additional cardiovascular risk factors may
beneﬁt from a single pill. Screening of those who may beneﬁt
should be based on self-reported adherence rather than PDC
levels.
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OBJECTIVES: Describe characteristics of drug prescribing pat-
terns of antihypertensive agents using sequence analysis. With
frequent changes in drug classes, sequence analysis can help illus-
trate the number and length of different drugs prescribed for
treatment. METHODS: Medstat’s MarketScan Database from
2003–2004 was used to identify a sample of newly diagnosed
hypertensive patients with 6 months continuous follow-up
administrative claims data. Drugs evaluated in each follow-up
month were ACEI, ARB, BB, CCB, diuretic, combination AHY
regimens, or none. For each patient, a sequence pattern is deﬁned
as an ordered list of drugs prescribed. Characteristics of patterns
are described and visualizations were made using index plots 
and parallel-coordinates plots. RESULTS: Eighty-seven different
sequences were identiﬁed among 387 patients studied. The three
most frequent sequences observed were 6 continuous months on
diuretic (16%), 6 months on ACE (14%), and 6 months on BB
(12%). Nineteen percent of patients had no drug after the ﬁrst
month, 40% had at least one month on “no” drug, and the
average duration on “no” drug was 1.4 (SE = 0.05) months.
Patients used an average of 1.7 (SE = 0.1) different drugs. Thirty-
eight percent of patients had some diuretic use and 15% had 6
months on diuretic. There were no signiﬁcant age or gender dif-
ferences in number and average length of drug episodes (a string
of months on same drug), but females had more and longer
episodes of “no” drug. Index plots with drug episodes charac-
terized by different colors show changes among diuretics occur
quicker and more frequently than among other drug classes.
CONCLUSION: Sequence analysis is used in many scientiﬁc
ﬁelds and is an unused tool that health economics can use for
summarizing changes in antihypertensive and other medications.
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OBJECTIVES: The purpose of this study was to validate the
health-related quality of life (HRQL) component of a hybrid
instrument IMPACT (Impact of Pharmacist Activities and Care
on Treatment outcomes) that is being developed to measure
patient satisfaction with pharmacist services and HRQL when
patients with multiple chronic conditions receive care in a phar-
macist-run medication therapy management (MTM) clinic.
METHODS: The HRQL component (developed following a 
systematic literature review and qualitative survey of patient 
and provider responses) had 24 items in ﬁve domains (physical,
social, emotional functioning, diet and medication-related
issues). The instrument was pretested on second year pharmacy
students at our institution to determine its psychometric prop-
erties (reliability, construct validity and responsiveness). Student
participants received the same baseline scenario (1) of a patient
with diabetes, hypertension and dyslipidemia and were random-
ized to receive one of two endings (2A or 2B). Scenario 2A
described patient status where a positive change in health status
occurred due to pharmacist intervention and Scenario 2B when
there was no change. Participants signed a consent form and
completed web-based pre and post HRQL surveys. Reliability
was tested using Cronbach’s alpha; responsiveness (sensitivity
